Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 23, 2025-

#Breakthrough Innovations in Neuropsychiatry Vistagen?s Advancements in Treating Social Anxiety Disorder with Pherines

Recent developments in the field of neuropharmacology have opened new avenues for the treatment and understanding of psychiatric disorders, particularly social anxiety disorder (SAD). This article reviews the latest initiatives by Vistagen Theraputics (NASDAQ: VTGN), a clinical-stage biopharmaceutical firm that is pioneering nose-to-brain neurocircuitry to develop a unique class of intranasal therapeutic agents termed pherines. Key updates from …